ngspan | 1026
NGS Pancreas Carcinoma
Keywords
BRCA1, BRCA2, CDK12, HRR, KRAS, Next Generation Sequencing, NRG1, PALB2, Pancreas
| Material |
|
|
| Note |
Complete gene sequencing of HRR-associated genes including BRCA1, BRCA2, PALB2; including KRAS, CDK12, as well as solid tumor DNA panel analysis (523 genes) and solid tumor fusion panel analysis (54 genes). Additionally, Genomic Instability Score (GIS), microsatellite instability (MSI), and tumor mutational burden (TMB) are reported. | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. Since, in rare cases, findings may also indicate hereditary changes, the Federal Act on Human Genetic Testing (HGTA) requires that patients be appropriately informed (see www.viollier.ch/consent_ssmg). The consent form is intended for internal documentation within the practice and does not need to be submitted to Viollier. Billing: in accordance with TARDOC. |
|
| Duration | 10 days | |
| Frequency | 1 x per week | |
| Method | Next Generation Sequencing, LDT | |
| Price | CHF 0.00 | |
| Tariff | 0.00 TP |
Team of consultants
|
Dr. med.
Katharina Marston
FMH Pathology, molecular pathology
|
FMH Pathology, molecular pathology | T |
|
|
Dr. rer. nat.
Henriette Kurth
FAMH Specialist in laboratory medicine, medical genetics
|
FAMH Specialist in laboratory medicine, medical genetics | T |
|
|
Dr. med.
Jean-François Egger
FMH pathology
|
FMH pathology | T |
|
|
PD Dr. med.
Andreas Zettl
FMH pathology, molecular pathology
|
FMH pathology, molecular pathology | T |
|
|
Dr. med.
Santiago Giménez de Mestral
FMH pathology, cytopathology
|
FMH pathology, cytopathology | T |
|